Biostax CORP

Quarterly Earnings (10-Q)

OTC.Pink
BTAX
Biostax CORP
10-Q: Biostax Corp Reports Q2 2024 Results with Ongoing Concerns About Financial Stability
Biostax Corp's Q2 2024 report reveals a net loss and negative cash flow, raising substantial doubt about the company's ability to continue as a going concern.
Worse than expected
Capital raise
OTC.Pink
BTAX
Biostax CORP
10-Q/A: Biostax Corp Restates Q1 2024 Financials Due to Accounting Errors
Biostax Corp has amended its Q1 2024 quarterly report to correct errors in the calculation of a derivative instrument and related party liabilities.
Worse than expected
Capital raise
OTC.Pink
BTAX
Biostax CORP
10-Q: Biostax Corp Reports First Quarter 2024 Results Amidst Going Concern Uncertainty
Biostax Corp reported a net loss of $337,076 for the first quarter of 2024 and faces significant challenges regarding its ability to continue as a going concern.
Worse than expected
Delay expected
Capital raise

Annual Reports (10-K)

OTC.Pink
BTAX
Biostax CORP
10-K/A: Biostax Corp Files Amended 10-K After Identifying Accounting Errors
Biostax Corp has filed an amended 10-K to correct errors in intangible assets, notes payable, and related party liabilities, and to include previously missing exhibits.
Delay expected
Capital raise
Worse than expected
OTC.Pink
BTAX
Biostax CORP
10-K: Biostax Corp Files 10-K, Outlines Strategy for Growth in Pharmaceutical and Biotech Sectors
Biostax Corp's 2023 10-K filing details its strategic focus on acquiring, developing, and commercializing pharmaceutical and biotechnology products, leveraging a hub-and-spoke model.
Delay expected
Capital raise
Worse than expected